New cancer clinical trial: Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Published on: January 25, 2019 at 12:00PM
Conditions:   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage III Merkel Cell Carcinoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Clinical Stage IV Merkel Cell Carcinoma AJCC v8;   High-Frequency Microsatellite Instability;   Metastatic Basal Cell Carcinoma;   Metastatic Melanoma;   Metastatic Skin Squamous Cell Carcinoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Merkel Cell Carcinoma AJCC v8;   Unresectable Melanoma
Interventions:   Biological: Ipilimumab;   Biological: Nivolumab;   Drug: Prednisone;   Drug: Tacrolimus
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting
http://bit.ly/2HyXbVA